DUBLIN, Ireland, Nov. 23, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery feasibility and option agreement with Rebel Pharmaceuticals, LLC, on two undisclosed compounds. The agreement will evaluate the ability of Merrion's patented GIPET® technology to enhance the compounds' clinical profile and provide a substantially improved product. On successful completion of the feasibility agreement, Merrion and Rebel Pharmaceuticals will enter into license agreements; the financial terms, including milestones and royalties, have already been agreed. Rebel Pharmaceuticals is a speciality Pharmaceuticals Company focused on enhancing approved drugs using proven and patented drug delivery technologies.
